Cigna Says 2027 Growth Starts From A $30 Run Rate, Below Its Raised $30.60 Outlook

Exiting ACA exchanges is a roughly $200 million headwind, yet Cigna still promises at least 10% adjusted EPS growth next year.

Share
Cigna Says 2027 Growth Starts From A $30 Run Rate, Below Its Raised $30.60 Outlook

Cigna's 2027 growth pledge is measured from a 2026 run rate of about $30 a share, CFO Ann Dennison told analysts on the company's third-quarter earnings call Thursday, below the full-year outlook of at least $30.60 that CEO Brian Evanko announced on the same call.

Why the base is $30, not $30.60

Cigna Group, a health company that runs a pharmacy benefit business and sells health insurance, is leaving the ACA exchange market. Dennison said the exchange business should stay profitable in 2026, though with margins a little below its 4% to 6% target range, and that runoff and stranded overhead costs will linger next year.

Based on current estimates, she said, that is an approximately $200 million headwind in Cigna Healthcare, which produces a 2026 run-rate adjusted EPS of approximately $30. Cigna remains confident of at least 10% adjusted EPS growth in 2027 from that base, which she called "a prudent starting point."

A Bank of America analyst asked how much of the drag could be recaptured in 2028 and beyond. Dennison said the company would look to get out any runoff costs and stranded overhead once the business is exited. Full 2027 guidance is due on the fourth-quarter call.

Evernorth earnings seen up low single digits

Dennison said Evernorth, which manages drug benefits and runs specialty pharmacies, should see 2027 earnings up low single digits. Specialty and care services should land near the low end of its 8% to 12% long-term range, with a thinner pipeline of biosimilar and specialty generic launches. Evanko said that implies pharmacy benefit services income falls by a single-digit percentage, pressured by shrinking industry rebate pools and fewer employers covering GLP-1 weight-loss drugs.

Evanko called 2026 and 2027 transitional years for pharmacy benefits. He said Cigna is still confident of adjusted EPS of at least $45 in 2030 and of the 10% to 14% average annual growth framework laid out at its investor day.

Selling season and savings

Evanko said the 2027 selling season is strong, with client retention in the high 90s and the company tracking to at least 2 million new pharmacy benefit customers.

Dennison said the Accelerate to One productivity program targets $3 billion in gross run-rate savings by 2030, with some reinvested in the business. For the third quarter, Cigna reported adjusted revenue of $73.8 billion and adjusted earnings of $7.98 a share.

Cigna's fourth-quarter call is where management says it will give full 2027 guidance, including segment detail.

Sources

More on Cigna Group

All Cigna Group (CI) coverage →